We are international
Donate
TEXT SIZE   
back

Myeloma Minute
February 21, 2013
02.21.13
February 21, 2013
Share the Minute Facebook Tweet! Clinical Trials Donate to the IMF
 



Upcoming Events


Saturday, March 23, 2013
Jacksonville Myeloma Center Workshop
Jacksonville, Florida




Saturday, April 20, 2013
Milwaukee Regional Community Workshop
Milwaukee, Wisconsin


May 10-11, 2013
SF/Bay Area Patient & Family Seminar
Redwood City, California

March is Myeloma Awareness Month! Lots of Ways to Spread the Word
Did you know that myeloma is the second most common blood cancer? Or that it affects an estimated 750,000 people worldwide? You may know everything about myeloma, but do your co-workers, friends or neighbors? Now's your chance to clue them in. March is Myeloma Awareness Month and the IMF has created an array of ways you can help expand the public's knowledge about the disease. From cool Myeloma Awareness buttons and digital Myeloma ribbons for your Facebook page, to live chats with IMF Chairman and Co-founder Brian G.M. Durie, MD, we're putting on a full-court press to help spread the word. READ MORE

x
Brian G.M. Durie, MD, on NPR's "Morning Edition"
Join the more than 12 million listeners who heard Dr. Brian Durie interviewed for a story that aired February 18 on National Public Radio's "Morning Edition," about the changing landscape of myeloma treatments.. The availability of targeted cancer drugs, "really has changed the whole landscape for both the doctor and the patient," Dr. Durie told NPR correspondent Richard Knox. Also featured in the report was myeloma patient Don Wright, who has run in 70 marathons since his diagnosis 10 years ago at the age of 62. READ MORE

New Clinical Trial Opens Under Direction of IMF Nurse Leadership Board Member
Enrollment is open for a new clinical trial at the Cleveland Clinic led by IMF Nurse Leadership Board member Beth Faiman, PhDc, MSN, APN-BC, AOCN, of the Cleveland Clinic Taussig Cancer Institute. "Glutamine in Preventing Peripheral Neuropathy in Patients with Multiple Myeloma Receiving Bortezomib" is a randomized Phase II trial that studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. Glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy.

Oral Anticancer Access Legislation Moves Forward in Oklahoma and Utah
On February 14th both the State House and State Senate in Oklahoma passed oral anticancer access legislation out of the insurance committees. Also, compelling testimony in Utah on Tuesday led to unanimous passage from their Senate Business and Labor Committee and is now onto the full State Senate. Seven other states are considering similar bills, which are imperative for myeloma patients on oral anticancer treatments who are forced to pay high out-of-pocket costs in co-insurance. The IMF believes that patients should not have to worry about affording treatment critical to their survival and well being. Visit the Action Center to see if your state is considering legislation this year and Take Action today.

 

 
Join Our Mailing List  
 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe 
www.myeloma.org

 related articles